World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Indiaâs Supreme Court to Hear Dispute on Drug Patents
Keywords:
Achieving a right balance between the needs for public health in developing countries- and the need for cost reduction in developed countries- with the need to keep innovation, is the challenge facing the Indian Supreme Court as it hears the Novartis case on its leukemia drug Gleevec. The efforts by Novartis and other western pharmaceutical companies to restrict the flow of low cost generic drugs from India. India stopped granting patents on drugs in 1970. It only resumed giving patents under a WTO agreement on patents. The Indian government denied the patent on Gleevec and the case is now coming up before the Supreme Court.
Novartis' leukemia drug Gleevec case before India's Supreme Court
03/06/2012
Grouped Articles
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Novartis Earnings Fall on Slide in Cancer-Drug Sales
Wall Street Journal 04/22/2016
Indian pharmaceutical companies and export markets.
02/09/2006
Grouped Articles
Indian Drugmakers Target Niche Markets
Wall Street Journal 04/19/2016
In Trade Deal, a Shift on Generics
Wall Street Journal 05/17/2007
Economist 11/08/2007
India's Drug Firms May Boost a Healthy Portfolio
Wall Street Journal 12/17/2007
Indian Companies Hit Their Stride
BusinessWeek 09/17/2007
BusinessWeek 09/04/2008
Indian pharmaceutical companies and the growing demand in India.
02/09/2006
The rapidly growing Indian pharmaceutical companies. The Indian market $8 billion today will grow to $30 billion in the next 10 years as more people get access to better healthcare. Sales in the Middle East, Africa and Latin America, and outsourcing manufacture for western companies are additional sources of growth for these companies.
Grouped Articles
Looking East, Big Pharma Cuts Prices
BusinessWeek 04/15/2010
India Administers Price-Cap Dose to Drug Companies
Wall Street Journal 09/22/2014
Indian Drug Maker Vies for Betapharm
Wall Street Journal 02/09/2006
Economist 11/08/2007
India's Drug Firms May Boost a Healthy Portfolio
Wall Street Journal 12/17/2007
Indian Companies Hit Their Stride
BusinessWeek 09/17/2007
Intellectual property issues, pricing and the Indian pharmaceutical industry
02/11/2012
Grouped Articles
India Administers Price-Cap Dose to Drug Companies
Wall Street Journal 09/22/2014
India-E.U. trade pact could boost AIDS treatment costs, health workers say - The Washington Post
Washington Post 02/11/2012
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Top Court in India Rejects Novartis Drug Patent
New York Times 04/01/2013
Foreign acquisitions of Indian pharmaceutical companies
09/27/2011
Grouped Articles
Indian Drugmakers Target Niche Markets
Wall Street Journal 04/19/2016
Wall Street Journal 09/27/2011
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
No Miracle Cure From Pharmaceutical Mergers
Wall Street Journal 04/07/2012
Wall Street Journal 04/26/2012
Acquisitions by Indian pharmaceutical companies.
02/09/2006
Grouped Articles
Indian Drugmakers Target Niche Markets
Wall Street Journal 04/19/2016
Indian Drug Maker Vies for Betapharm
Wall Street Journal 02/09/2006
Indian Companies Hit Their Stride
BusinessWeek 09/17/2007
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
No Miracle Cure From Pharmaceutical Mergers
Wall Street Journal 04/07/2012
Novartis in China and emerging markets.
10/02/2006
Grouped Articles
China Worries Could Hurt Pharma’s Health
Wall Street Journal 08/24/2015
Novartis Cuts Price of Coartem To Help Fight Malaria in Africa - WSJ.com
Wall Street Journal 10/02/2006
Novartis to Establish Drug R&D Center in China - WSJ.com
Wall Street Journal 11/06/2006
Novartis Angers Critics in India
Wall Street Journal 03/05/2007
India Rejects Novartis Patent Claim
Wall Street Journal 07/07/2009
Novartis Mounts Ambitious Push Into China
Wall Street Journal 11/04/2009
Glaxo in the pharmaceutical market in China
04/15/2010
Grouped Articles
GlaxoSmithKline Probes Bribe Allegations in China
Wall Street Journal 06/12/2013
Wall Street Journal 07/16/2013
Glaxo Cites Possible Violations in China
Wall Street Journal 07/23/2013
Looking East, Big Pharma Cuts Prices
BusinessWeek 04/15/2010
Glaxo Names New China Chief Amid Bribery Probe
Wall Street Journal 07/26/2013
Wall Street Journal 10/24/2013
Reinventing drugs, another method to boost sales used by pharmaceutical companies.
09/29/2006
By combining drugs that have lost protection with some other ingredient to make product extensions, companies like Glaxo have generated continued sales growth. Glaxo does this with Treximet for migraines.
Grouped Articles
A J&J Copycat Could Extend Old Drug's Life - WSJ.com
Wall Street Journal 09/29/2006
Glaxo Becomes Master of Reinventing Drugs
Wall Street Journal 04/17/2008
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Glaxo Tries to Shake Marketing Questions on Advair
Wall Street Journal 07/06/2012
Anemia drug made billions, but at what cost? - The Washington Post
Washington Post 07/20/2012
Abbott in emerging markets.
02/26/2009
Grouped Articles
Emerging Markets Are on Their Own
Wall Street Journal 06/23/2013
Looking East, Big Pharma Cuts Prices
BusinessWeek 04/15/2010
Abbott Plant Is New Move To Tap Asia
Wall Street Journal 02/26/2009
Abbott Labs to Buy Indian Drug Maker
Wall Street Journal 05/22/2010
Abbott Labs to Buy Indian Drug Maker
Wall Street Journal 05/22/2010
Abbott Labs Spices Up Its Drug Portfolio
Wall Street Journal 05/22/2010
Abbott Labs strategies
10/19/2006
Grouped Articles
Abbott Labs Spices Up Its Drug Portfolio
Wall Street Journal 05/22/2010
Abbott Labs to Buy Indian Drug Maker
Wall Street Journal 05/22/2010
Abbott to Split Into Two Companies
Wall Street Journal 10/20/2011
Abbott Labs Licenses Molecules from Reata
Wall Street Journal 12/12/2011
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Abbott Looks to Consumer for Growth
Wall Street Journal 05/03/2012
Pfizer in emerging markets
04/15/2010
Grouped Articles
Looking East, Big Pharma Cuts Prices
BusinessWeek 04/15/2010
Abbott Looks to India for Shot in Arm
Wall Street Journal 08/26/2010
Pfizer's New CEO Challenged Overseas
Wall Street Journal 12/10/2010
Life Beyond Lipitor for Pfizer Chief
Wall Street Journal 05/02/2011
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Pfizer Profit Declines 19% After Loss of Lipitor Patent
New York Times 05/01/2012
Indian pharmaceutical manufacturer Ranbaxy performance
03/06/2012
Grouped Articles
Generic-Drug Firms Go Beyond Knockoffs
Wall Street Journal 06/15/2013
Daiichi Sankyo to Sell Troubled Ranbaxy
Wall Street Journal 04/08/2014
India Administers Price-Cap Dose to Drug Companies
Wall Street Journal 09/22/2014
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Generic Drug Makers Facing Squeeze on Revenue
New York Times 12/03/2012
India's Supreme Court and Novatis leukemia drug Gleevec
03/06/2012
The issues of what drugs are patentable in India,"evergreening" for patents, and public health concerns throughout developing countries, that are now before the Indian Supreme Court. India permitted the patenting of drugs only since 2005 under a WTO agreement, and there are restrictions on "evergreening," or small modifications of existing drugs for marketing. Novartis and other pharmaceutical companies aim to use the case to restrict Indian generic pharmaceuticals manufacturers from coming up with lowcost versions of new drugs. The leukemia treatment developed by Novartis costs over $70,000, by comparison Indian generic manufacturers can make a version of this for $2500.
Grouped Articles
India Orders Bayer to License Patented Cancer Drug
New York Times 03/12/2012
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
Three Days Of Hearings Yield Five Take-Aways
Wall Street Journal 03/29/2012
Top Court in India Rejects Novartis Drug Patent
New York Times 04/01/2013
Indian pharmaceutical companies and patent challenges.
07/07/2009
Grouped Articles
India Orders Bayer to License Patented Cancer Drug
New York Times 03/12/2012
India Rejects Novartis Patent Claim
Wall Street Journal 07/07/2009
India Prepares EU Trade Complaint
Wall Street Journal 08/06/2009
India-E.U. trade pact could boost AIDS treatment costs, health workers say - The Washington Post
Washington Post 02/11/2012
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
AARP Study Says Price of Popular Drugs Rose 26%
New York Times 03/06/2012
India's exports- 2010-2013
07/25/2011
The shift in exports from textiles to automobiles, automotive, petrochemical, pharmaceutical and engineering goods. Manufactured goods at $245 billion for 2010 are now twice as large as IT services in India's exports.
Grouped Articles
Rupee Continues Decline on New Evidence of Weakness in Indian Economy
New York Times 09/02/2013
Manufactured Goods Lead Surge in Indian Exports
New York Times 07/25/2011
India-E.U. trade pact could boost AIDS treatment costs, health workers say - The Washington Post
Washington Post 02/11/2012
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Rupee Plunges to an All-Time Low
Wall Street Journal 06/22/2012
Top Court in India Rejects Novartis Drug Patent
New York Times 04/01/2013
Outsourcing production to India and China by pharmaceutical companies.
05/29/2007
FDA's efforts to ensure safety by inspecting facilities.
Grouped Articles
China Worries Could Hurt Pharma’s Health
Wall Street Journal 08/24/2015
China Sentences Former Drug Regulator to Death
New York Times 05/29/2007
China Faces a New Worry: Heavy Metals in the Food
Wall Street Journal 07/02/2007
China-Product Scare Hits Home, Too
Wall Street Journal 07/20/2007
India's Drug Firms May Boost a Healthy Portfolio
Wall Street Journal 12/17/2007
BusinessWeek 09/04/2008
Glaxo partnerships with other pharmaceutical companies.
07/07/2008
Partnersuip wit Dr. Reddy's in India and South Africa's Aspen Pharmacare.
Grouped Articles
Glaxo Seeks Guidance From Health Systems
Wall Street Journal 07/07/2008
Glaxo and Pfizer Join Forces to Develop and Market H.I.V. Drugs
New York Times 04/17/2009
Glaxo Seals Marketing Pact With Dr. Reddy's
Wall Street Journal 06/16/2009
The Four Ps of Global Business Expansion
Wall Street Journal 11/12/2010
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Wall Street Journal 05/11/2012
Novartis drug development 2010-2015
11/12/2010
Grouped Articles
Novartis Starts $5 Billion Share Buyback
Wall Street Journal 11/22/2013
Novartis Replaces Top Management in Japan
Wall Street Journal 04/04/2014
Wall Street Journal 11/12/2010
Novartis's MS Drug Gets Approval from EU
Wall Street Journal 03/21/2011
How Novartis Plans to Avoid the 'Patent Cliff'
BusinessWeek 08/04/2011
Wall Street Journal 09/13/2011
Novartis strategies
02/04/2010
Grouped Articles
BusinessWeek 02/04/2010
Splitting the Pill at Novartis Will Be Easier Said Than Done
Wall Street Journal 11/18/2013
Novartis Starts $5 Billion Share Buyback
Wall Street Journal 11/22/2013
Novartis Seals Purchase of Big Alcon Stake
Wall Street Journal 08/27/2010
Novartis Chairman Stresses Need for R&D Investment
Wall Street Journal 03/22/2014
Wall Street Journal 04/23/2014
Meeting the cost concerns of governments and insurers. Efforts by pharmaceutical companies.
11/09/2006
Efforts by companies like GlaxoSMithKline to meet cost concerns of governments by linking pricing to the effectiveness of the drugs or treatments. Pharmaceutical pricing an issue with governments.
Grouped Articles
Wall Street Journal 11/09/2006
Glaxo Chief Charts New Growth Strategy
Wall Street Journal 06/10/2008
Pricey Drugs Put Squeeze on Doctors
Wall Street Journal 07/08/2008
Drug Makers Trim Prices for Health Overhaul
Wall Street Journal 06/22/2009
For Drug Makers, Concessions Have a Bright Side
Wall Street Journal 06/23/2009
New York Times 06/25/2009
Glaxo research and development.
03/27/2006
R&D at Glaxo SmithKline
Grouped Articles
Bureaucracy Buster? Glaxo Lets Scientists Choose Its New Drugs
Wall Street Journal 03/27/2006
BusinessWeek 05/08/2008
Glaxo Is Eliminating R&D Jobs As Part of Cost-Cutting Plan
Wall Street Journal 06/12/2008
Glaxo Aims to Cut R&D Staff by 6%
Wall Street Journal 09/30/2008
Wall Street Journal 05/26/2010
Glaxo Tries Biotech Model to Spur Drug Innovations
Wall Street Journal 07/01/2010
Abbott Labs acquisitions.
10/19/2006
Grouped Articles
Abbott Buys Drug Maker in India for $3.7 Billion
New York Times 05/21/2010
Abbott Labs Spices Up Its Drug Portfolio
Wall Street Journal 05/22/2010
Abbott Labs to Buy Indian Drug Maker
Wall Street Journal 05/22/2010
Abbott Looks to India for Shot in Arm
Wall Street Journal 08/26/2010
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Abbott Looks to Consumer for Growth
Wall Street Journal 05/03/2012
Pfizer and Generic manufacturers.
01/17/2006
Grouped Articles
Pfizer Bets $15 Billion on New Class of Generic Drugs
New York Times 02/05/2015
Branded Drugs Settling More Generic Suits
Wall Street Journal 01/17/2006
Pfizer, Ranbaxy Reach Lipitor Deal
Wall Street Journal 06/18/2008
Generic Lipitor Sets Off an Aggressive Push by Pfizer
New York Times 11/29/2011
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Pfizer Profit Declines 19% After Loss of Lipitor Patent
New York Times 05/01/2012
Indian pharmaceutical manufacturer Cipla
03/06/2012
Grouped Articles
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Top Court in India Rejects Novartis Drug Patent
New York Times 04/01/2013
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us
